AbbVie Acquires Celsius Therapeutics
What role does TREM1 play in IBD?
TREM1 is a key disease driver gene in inflammatory bowel disease (IBD), where it is expressed on inflammatory monocytes and neutrophils. It acts as an amplifier of inflammation, and its engagement on the surface of macrophages in IBD patients results in enhanced production of pro-inflammatory molecules such as TNF, IL-6, IL-8, and MCP-1. Inhibiting TREM1 signaling has been shown to reduce inflammation in preclinical studies, making it a potential therapeutic target for IBD treatment.
Who acquired Celsius Therapeutics?
AbbVie, a research-based global biopharmaceutical company, acquired Celsius Therapeutics, a privately held biotechnology company focused on developing novel therapies for patients with inflammatory disease. The acquisition was announced on June 27, 2024.
What are the expected outcomes of CEL383's further development?
CEL383, a potential first-in-class anti-TREM1 antibody, aims to offer a new approach to treating inflammatory bowel disease (IBD). The further development of CEL383 could help more patients with IBD achieve remission by inhibiting TREM1 signaling and reducing levels of multiple inflammatory mediators. As a result, it may provide a clinically meaningful treatment option and improve the quality of life for people suffering from IBD.